(All times are in Central Standard Time)

Ancillary Educational Events
(In-person only, not available for online or virtual viewing)

Lancet Breast Cancer Session
Location: Room 221ABC

The Do's & Don'ts of Communication on Advanced/Metastatic Breast Cancer
Location: Room 221ABC
An ABC Global Alliance and MBC Alliance workshop on enhancing communication on challenging health decisions

SABCS Program Begins

Risk Reduction and Early Detection: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction
Location: Hemisfair Ballroom 1-2

Moderator: Carol Fabian, University of Kansas Medical Center, Westwood, Kansas

• Genetic and Epigenetic Changes in Response to Caloric Restriction and Physical Activity
  Catherine Duggan, Fred Hutchinson Cancer Center, Seattle, Washington

• Achieving Sufficient Fat Loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (Nutrient Sensing Hormone (NUSH) - Based Therapeutics
  Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York
• Impact and Types of Exercise and Pharmacotherapy in Weight Loss
  John Jakicic, University of Kansas Medical Center, Westwood, Kansas
• Panel Discussion

FDA Special Session: New Drug Approvals
Location: Stars at Night 3-4

Moderator: Laleh Amiri Kordestani, FDA, Silver Spring, Maryland, and Eric Winer, Yale University, New Haven, Connecticut

Patient Advocate:  Victoria Goldberg, New York, New York

• Adjuvant Ribociclib
  Jennifer Gao, FDA, Silver Spring, Maryland
• Panel Discussion
   
• Inavolisib Approval
  Suparna Wedam, FDA, Silver Spring, Maryland
• Panel Discussion
   
• Monitoring of Ovarian Toxicity During Clinical Trials
  Antonio Wolff, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
• Panel Discussion

Special Session 3: Sex, Drugs, Rock and Roll
Location: Stars at Night 1-2

Moderator: Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Patient Advocate:  Tomika Bryant, King of Prussia, Pennsylvania

• Supplements and Cannabis
  Heather Greenlee, Fred Hutchinson Cancer Center, Seattle, Washington
• Sexual Health
  Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island
• Exercise During Treatment
  Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York
• Eating and Drinking
  Lawrence Kushi, Kaiser Permanente Northern California, Pleasanton, California
• Panel Discussionon

Career Development:  Navigating the Road to Success - Early Funding for Research and Beyond
Location: Room 221ABC

Moderator: Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

• Federal Funding Opportunities
  Larissa Korde, Johns Hopkins School of Medicine, Washington, D.C.
• Foundation and Community Program Support
  Sara Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts
• Industry Interactions and Funding Programs
  Minetta Liu, Natera, Austin, Texas
• Panel Discussion

Clinical Workshop: Dose Optimization in Breast Medical Oncology
Location: Stars at Night 1-2

Moderators: Mirat Shah, FDA, Silver Springs, Maryland, and Patricia LoRusso, Yale School of Medicine, New Haven, Connecticut

Speakers and Panelists: Stacy Shord, Julia Maues, Mallorie Fiero, and Michael Ignatiadis

Part A:

• Why Now? The Need for Dosage Optimization in Oncology.
  Patricia LoRusso, Yale School of Medicine, New Haven, Connecticut
• The Nuts and Bolts of Dosage Optimization
  Stacy Shord, FDA, Silver Springs, Maryland
• What is Regimen Optimization and Why do We Need It
  Mirat Shah, FDA, Silver Springs, Maryland
• A Dose of Reality: The Patient Perspective
  Julia Maues, Patient Advocate, Baltimore, Maryland

Discussion/Q&A: Everyone

Part B:

• Lack of Crossover in Clinical Trial Design
  Michael Ignatiadis, Institut Jules Bordet, Brussels, Belgium

Discussion/Q&A: Everyone 

2:00 – 3:45 pm
 

Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials
Location: Stars at Night 3-4

Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium

• Multiplex Imaging for Precision Oncology
  Raza Ali, Cancer Research UK, Cambridge, United Kingdom
• Single Cell T-Cell Receptors and B-Cell Receptors
  Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium
• Spatial Transcriptomics
  Christos Sotirou, Institut Jules Bordet, Brussels, Belgium
• Cancer Immunology Discovery Approaches into Clinical Trials
  Emanuela Romano, Institut Curie, Paris, France
• Panel Discussion

Career Development: Patient Driven Protocol Development
Location: Room 221ABC

Moderator: Saranya Chumsri, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, and Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

Patient Advocate: Debora Denardi, Miami Beach, Florida

• Importance of Partnerships in Clinical Research
  Edith Perez, Mayo Clinic, Kenwood, California
• Designing Patient-centric Clinical Trials
  Tatiana Prowell, FDA, Silver Spring, Maryland 
• Novel Statistical Designs: Putting Patients First
  Amylou Dueck, Mayo Clinic Cancer Center, Scottsdale, Arizona

4:00 – 5:45 pm
 

Educational Session 1: Mind the Gap — Breast Cancer in the Young
Location: Stars at Night 1-2

Moderator: Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico, San Martino, Genoa, Italy

Patient Advocate: Na'Diah Smith, Dallas, Texas

• Biology of Breast Cancer in Young Women
  Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
• Ovarian Suppression: Who, When, Why, and for How Long
  Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia
• Survivorship
  Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland
• Panel Discussion

4:00 – 5:45 pm
 

Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment
Location: Hemisfair Ballroom 1-2

Moderator: Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania

Patient Advocate: Ellen Landsberger, New York City, New York

• Review of Current Technologies
  Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts
• Early Detection and Molecular Recurrent Disease
  Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee
• Utility in the Metastatic Setting
  David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada
• Case Discussion
• Panel Discussion

4:00 – 5:45 pm

Educational Session 3: Tumor Heterogeneity and Evolution
Location: Hemisfair Ballroom 3

Moderator: Reuben S. Harris, UT Health San Antonio, San Antonio, Texas

• Identification of Aneuploid Epithelial Cells in Normal Breast Tissues
  Nicholas Navin, MD Anderson Cancer Center, Houston, Texas
• Genomic and Microenvironment Determinants of Breast Cancer Progression
  Christina Curtis, Stanford University, Stanford, California
• Single Cell Genomics in Triple Negative Breast Cancer
  Ashley Laughney, Weill Cornell Medicine, New York, New York
• Panel Discussion

4:00 – 5:45 pm

Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment 
Location: Stars at Night 3-4

Moderator: Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain

Patient Advocate: Beth Emery, The Woodlands, Texas

• Neoadjuvant Management and Adaptive Strategies
  Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands
• Treatment of Small Tumors in Early-Stage Setting
  Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
• Post Neoadjuvant Management for non pCR
  Joyce O'Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas
• Panel Discussion

Late-Breaking Oral Presentations
Location: Stars at Night 1-2

Moderator: Rita Nanda, University of Chicago Medicine, Chicago, Illinois

LB1-01: Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women.
Robert Hills, University of Oxford, Oxford, United Kingdom

LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer.
Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts

LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study.
Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany

LB1-04: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06.
Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC).
Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.
Joyce  O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas

(All times are in CST)

Concurrent Poster Spotlight Sessions 1, 3, 4, 5, 7

Session 1: New Insights into Immune Biomarkers
Location: Room 221ABC

Moderator: David Rimm, Yale University

Poster Viewing 7:00 – 7:30

PS1-01: Tumor Infiltrating Lymphocytes (TILs) as a Predictive Marker of Pathological Complete Response (pCR) in a Diverse Patient Population with Early Triple Negative Breast Cancer (TNBC) Treated with the Neoadjuvant KEYNOTE-522 Regimen.
Riya Albert, UT Southwestern Medical Center, Dallas, Texas

PS1-02: Impact of racial differences in circulating blood components and stromal tumor-infiltrating lymphocytes (sTILs) on outcomes in triple negative breast cancer (TNBC).
Priyanka Sharma, University of Kansas Medical Center, Kansas City, Kansas

PS1-03: Prediction of Prognosis and Efficacy of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients Based on Tertiary Lymphoid Structures.
Kejing Zhang, Central South University, Changsha, China

PS1-04: Tumor-infiltrating lymphocytes (TILs) and response to neoadjuvant chemotherapy in young patients with breast cancer.
Megan Tesch, Dana-Farber Cancer Institute, Boston, Massachusetts

PS1-05: Genomic characteristics related to histology-based immune features in breast cancer.
Yoon Jin Cha, Yonsei University, Seoul, South Korea

PS1-06: Intratumor tumor-infiltrating lymphocytes (iTILs) and spatial distribution pattern of stromal TILs (sTILs) evaluated by HALO AI are prognostic indicators of triple-negative breast cancer.
Makiko Fukumura-Koga, National Defense Medical College, Tokorozawa, Japan

PS1-07: Al-Derived Tumor-Infiltrating Lymphocytes Enhance the Model with Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Predicting Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.
Xiaoxi Pan, Institute of Cancer Research, London, United Kingdom

PS1-08: Deciphering the Tumor-Immune Landscape and Mechanisms of Response and Resistance to Neoadjuvant Therapy in Early-Stage Breast Cancer Using Single-Cell RNA Sequencing.
Marcela Carausu, Institut Jules Bordet in Brussels, Belgium

7:30-7:45 Discussant (PS1-01, PS1-02, PS1-03, PS1-04)
The Patient and Subtype of Breast Cancer
Frederique Penault Llorca, University of Clermont-Ferrand, Clermont-Ferrand, France

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS1-05, PS1-06, PS1-07, PS1-08)
Spatial and Cellular Arrangements
Theo Foukakis, Karolinska Institutet, Solina, Sweden

8:15-8:30 Panel Q&A

Session 3: Highlights on Novel Therapeutics
Location: Stars at Night 1-2

Moderator: Sara Tolaney, Dana-Farber Cancer Institute

Poster Viewing 7:00 – 7:30
PS3-01: Tislelizumab plus sitravatinib and nab-paclitaxel in patients with untreated locally recurrent or metastatic triple negative breast cancer (TNBC): updated efficacy and safety results.
Xiyu Liu, Fudan University Cancer Institute, Shanghai, China

PS3-02: Induction of Cisplatin/abraxane/pembrolizumab followed by pembrolizumab ± Olaparib Maintenance in triple-negative Metastatic breast cancer patients (COMPLEMENT) – A Randomized, Open-label, Phase II Study.
Xichun Hu, Fudan University Cancer Institute, Shanghai, China

PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial.
Christian F. Singer,  Medical University of Vienna, Vienna, Austria.

PS3-04: Overall Survival Results of Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine.
Saranya Chumsri, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida

PS3-05: Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC).
Xiaojia Wang, Zhejiang Cancer Hospital, Hangzhou Institute of  Medica（HIM) , Chinese Academy of Sciences, Zhejiang, China

PS3-07: SHR-A1811 as Neoadjuvant Treatment in Patients with HR-Positive, HER2-low Breast Cancer: The first-stage results from an open-label, single-arm, two-stage, phase II clinical trial.
Zhenzhen Liu, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

PS3-08: Interim Overall Survival of Patients with Locally Advanced or Metastatic Triple-Negative Breast Cancer treated wtih First Line PM8002/BNT327 in Combination with Nab-Paclitaxel in Phase Ib/II Study.
Jiong Wu, Fudan University Cancer Institute, Shanghai, China

7:30-7:45 Discussant (PS3-01, PS3-02, PS3-03, PS3-04)
Innovative Immunotherapy Approaches in Breast Cancer
Heather McArthur, UT Southwestern, Dallas, Texas

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS3-05, PS3-07, PS3-08)
Targeted Powerhouses: The Role of Bispecific Antibodies, TKIs and ADCs in Breast Cancer.
Thomas Grinda, Gustave Roussy, Villejuif, France

8:15-8:30 Panel Q&A

Session 4: Prediction of Chemotherapy Response
Location: Stars at Night 3-4

Moderator: Sherene Loi, Peter Macallum Cancer Centre

Poster Viewing 7:00 – 7:30
PS4-01: Predictor of benefit from dose-dense paclitaxel chemotherapy for patients with hormone receptor-positive HER2-negative breast cancer. A GEICAM/9906 sub-study.
Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain

PS4-02: Patient-derived Xenografts (PDX) Allow Deconvolution of Combination Chemotherapy Response.
Jonathan Lei, Baylor College of Medicine, Houston, Texas

PS4-03: Calcium Channel Blockers Enhance Efficacy of TROP2-ADC in Overcoming Resistance in Advanced Triple-Negative Breast Cancer.
Jieer Luo, Sun Yat-sen Memorial Hospital, Guangzhou, China

PS4-04: MammaPrint® and BluePrint® predict pathological response to neoadjuvant chemotherapy in patients with HR+HER2- early-stage breast cancer enrolled in FLEX.
Joyce  O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas

PS4-06: HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab: Correlative Analysis from CLEOPATRA Phase III Trial.
Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain

PS4-07: Residual disease after HER2 inhibition is driven by a primary tumor subpopulation expressing an ERBB2-low associated transcriptional program.
Vittal Kurisetty, Roswell Park Comprehensive Cancer Center, Buffalo, New York

PS4-09: Spatial Omics Analysis Uncovers Microenvironmental Remodeling and Immune Dynamics in T-DXd Resistant Metastatic Breast Cancer.
Glori Das, Houston Methodist Neal Cancer Center

PS4-10: TNBC-DX Genomic Test Predicts High pCR in Triple-Negative Breast Cancer with sTILs ≥30% Treated with Neoadjuvant Docetaxel-Carboplatin with/without Pembrolizumab.
Shane Stecklein, University of Kansas Health System, Kansas City, Kansas

7:30-7:45 Discussant (PS4-01, PS4-02, PS4-04, PS4-06)
Prediction of Chemotherapy Response
Reshma Mahtani, Miami Cancer Institute, Miami, Florida

7:45-8:00 Panel Discussion

8:00-8:15 Discussant (PS4-03, PS4-07, PS 4-09, PS4-10)
Anti-HER2 strategies, ADCs and Chemotherapy
Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain

8:15-8:30 Panel Discussion

Session 5: The Heart of the Matter - Improving Adverse Effects
Location: Hemisfair Ballroom 3

Moderator: Anne Blaes, Masonic Cancer Center University of Minnesota

Poster Viewing 7:00 – 7:30

PS5-01: The association between pembolizumab and risk of venous thromboembolism in patients with breast cancer.
Cho-Han Chiang, Mount Auburn Hospital, Cambridge, Massachusetts

PS5-02: The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer.
Cho-Han Chiang, Mount Auburn Hospital, Cambridge, Massachusetts

PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study.
Alexis LeVee, City of Hope, Los Angeles, California

PS5-04: Anti-RANKL bone resorptive therapy increases immune-related adverse events (irAE) in breast cancer patients (pts) treated with pembrolizumab.
Alexis LeVee, City of Hope, Los Angeles, California

PS5-05: Late-onset immune toxicity incidence & risk factors in breast cancer: a multi-institutional study.
Saya Jacob, Northwestern Medicine-Northwestern Memorial Hospital, Chicago, Illinois

PS5-06: Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)
Andreas Müller, Kantonsspital Winterthur, Winterhur, Switzerland

PS5-07: Financial difficulty over time in young adults with breast cancer.
Sara Myers, Brigham and Women’s Hospital, Boston, Massachusetts

PS5-08: Effects of Cryotherapy on Objective and Subjective Symptoms of Taxane Induced Neuropathy in Patients with Early Breast Cancer: A National, Multicenter, Prospective, Randomized, Controlled Trial.
Maria Elisabeth Lendorf, Nordjaellands Hospital, Capital Region, Denmark

PS5-09: Feasibility of an Interactive Care Plan for Self-Management of Toxicity Symptoms and Surveillance for Non-Metastatic Disease in Breast Cancer Survivors.
Daniela Stan, Mayo Clinic, Rochester, Minnesota

7:30-7:45 Discussant (PS5-01, PS5-02, PS5-03, PS5-04, PS5-05)
Immunotherapy and adverse effects
Sarah Sammans, Dana-Farber Cancer Institute, Boston, Massachusetts

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS5-06, PS5-07, PS5-08, PS5-09)
Seen and Unseen Toxicities: Improving outcomes
Marcela Mazo Canola, UT Health Mays Cancer Center, San Antonio, Texas

8:15-8:30 Panel Q&A

Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations
Location: Hemisfair Ballroom 1-2

Moderator: Shom Goel, Peter MacCallum Cancer Centre

Poster Viewing 7:00 – 7:30
PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial.
Cristina Saura, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients.
Dejan Juric, Mass General Research Institute Cancer Center, Boston, Massachusetts

PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study.
Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

PS7-04: BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth alone and in combination with standard of care therapies in breast cancer models without inducing hyperglycemia.
Kerstein Sinkevicius, BioBridge Oncology Therapeutics, Palo Alto, California

PS7-05: Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).
Maxwell Lloyd, Beth Israel Deaconess Medical Center, Boston, Massachusetts

PS7-06: Elacestrant combinations in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase 1b/2, open-label, umbrella study.
Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS7-07: Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC).
Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS7-08: Results from SERENA-1 Parts K/L: A Phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer.
Richard Baird, University of Cambridge, Cambridge, United Kingdom

7:30-7:45 Discussant (PS7-01, PS7-02, PS7-03, PS7-04)
PI3K Inhibitors
Chris Vaklavas, Huntsman Cancer Institute, Salt Lake City, Utah

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS7-05, PS7-06, PS7-07, PS7-08)
SERD
Rinath Jeselsohn, Dana-Farber Cancer Institute, Boston, Massachusetts

8:15-8:30 Panel Q&A

Welcome and Opening Remarks

SABCS Co-directors
Carlos Arteaga, MD, UT Southwestern Medical Center, Dallas, Texas
Virginia Kaklamani, MD, UT Health Mays Cancer Center, San Antonio, Texas

Keynote Address

(Re)emerging Principles for Controlling Cancer with Drugs

William Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts

General Session 1
Location: Hall 1

Moderators: Alexandra Thomas, Duke Cancer Institute, Durham, North Carolina, and Reshma Mahtani, Miami Cancer Institute, Miami, Florida

GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial.
Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

GS1-02: Discussant about Ember 3
Harold Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts 

GS1-03: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial.
Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial.
Junjie Li, Fudan University Shanghai Cancer Center, Shanghai, China

GS1-05: Discussant about GS1-03, 04, and 05
Aleix Prat, Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain

GS1-06: PRO B – a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients.
Maria Margarete Karsten, Charité-Universitätsmedizin, Berlin

GS1-07: Discussant about GS1-06
Gabrielle Rocque, University of Alabama at Birmingham, Birmingham, Alabama

GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study.
Matteo Lambertini, University of Genova, Genova, Italy

GS1-09: OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow.
Judy Garber, Dana-Farber Cancer Institute, Boston, Massachusetts

William L. McGuire Memorial Lecture

Award presented by Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas

Laura J. van 't Veer, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Rapid Fire 1
Location: Hall 1

Moderator: Shom Goel, University of Melbourne Peter MacCallum Cancer Centre

RF1-01: Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance).
Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, Massachusetts

RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
Luca Malorni, USL Toscana Centro, Hospital of Prato, Prato, Italy

RF1-03: Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01).
Fleur Louis, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands

RF1-04: Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer.
Azka Ali, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois

RF1-05: DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.
Saya Dennis, Northwestern University Feinberg School of Medicine, Chicago, Illinois

RF1-06: Association of polygenic-based breast cancer risk prediction with patient management.
Katie Johansen Taber, Myriad Genetics, San Francisco, California

RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
Polly Niravath, Dr. Mary and Ron Neal Cancer Center, Houston, Texas

Risk Reduction and Early Detection: Updates on Breast Cancer Screening
Location: Stars at Night 3-4

Moderator: Ismail Jatoi, UT Health Mays Cancer Center, San Antonio, Texas

• Risk-Based Screening in the Average Population
  Karla Kerlikowske, University of California San Francisco, San Francisco, California
• Novel Imaging Modalities
  Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
• Screening for High-Risk Women: The Clinical Perspective
  Seema Khan, Northwestern University Feinberg School of Medicine, Chicago, Illinois
• Panel Discussion

Clinical Case Discussions
Location: Stars at Night 1-2

Moderator: Debra Patt, Texas Oncology, Austin, Texas

Patient Advocate: Kelly Shanahan, Tahoe, California

• Sonya Reid, Vanderbilt Ingram Cancer Center, Nashville, Tennessee
• Icro Meattini, Florence University Hospital, Florence, Italy
• Tari King, Dana-Farber Cancer Institute, Boston, Massachusetts
• Anne Salomon, Institut Curie, Paris, France
• Harold Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts
• Erika Hamilton, Sarah Cannon Cancer Network, Nashville, Tennessee

Navigating Success: Women’s Career Development
Location: Room 221ABC

Moderator: Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts 

Designed for women who have completed their training and are now in practice, this workshop is a dynamic and inclusive event aimed to inspire and support women pursuing careers in scientific research. The workshop provides a platform for accomplished female scientists to share their experiences, provide mentorship, and discuss strategies to overcome gender-related challenges in the field of cancer research. Through engaging talks, interactive sessions, and networking opportunities, participants gain valuable insights, build a stronger support network, and acquire practical tools to thrive and excel in their scientific research careers.

• Setting the stage for Success
  Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts 
• Evidence-based strategies to address systemic barriers facing women researchers
  Reshma Jagsi, Emory University, Atlanta, Georgia

State of the Art Session 1:
The Winding Road of Immune Biomarkers in Early Breast Cancer
Location: Stars at Night 3-4

Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

• TILs: An Update After 10 Years of Research
  Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia
• Immune Biomarkers Beyond TILs 
  Justin Balko, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
• Deploying Immune Biomarkers in Clinical Trials
  Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas 
• Panel Discussion

Translational Controversies
Location: Stars at Night 1-2

Moderator: Antonio Wolff, Johns Hopkins University, Baltimore, Maryland

• How to Define Triple Negative Breast Cancer
  Rebecca Dent, National Cancer Center Singapore, Singapore
  Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
• Tumor Agnostic Drug Development
  Funda Meric, MD Anderson Cancer Center, Houston, Texas
  Fabrice Andre, Institut Gustave Roussy, Villejuif, France

AACR Outstanding Investigator Award for Breast Cancer Research
Location: Stars at Night 1-2
Moderator: Sofia Merajver, University of Michigan Health Rogel Cancer Center, Ann Arbor, Michigan

Christina Curtis, Stanford University School of Medicine, Palo Alto, California

3:30 – 5:15 pm

Educational Session 5: Unlocking New Targets with Molecular Degraders
Location: Hemisfair Ballroom 3

Moderator: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas

• PROTACs
  Stephen Hinshaw, Stanford Cancer Institute, Palo Alto, California
• Lysosome-targeting Chimeras
  Weiping Tang, Tang Research Group, Univerisity of Wisconsin School of Pharmacy, Madison, Wisconsin
• Biparatropic Antibodies
  Saireudee Chaturantabut, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
• Latest on selective estrogen receptor degraders (SERDs)

  Rinath Jeselsohn, Dana-Farber Cancer Institute, Boston, Massachusetts

• Panel Discussion

Educational Session 6: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer - In honor of Dr. V. Craig Jordan
Location: Stars at Night 1-2

Moderators: William Gradishar, Northwestern University Feinberg School of Medicine, Chicago, Illinois, and Sara Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington

Case Presentations and Discussants:
Michael Oliphant, Harvard Medical School, Boston, Massachusetts
Marla Lipsyc-Sharf, UCLA Health, Santa Monica, California
Neil Vasan, Columbia University Irving Medical Center, New York, New York
Dan Stover, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Amy Beumer, Patient Advocate, Mason, Ohio

• Case 1: New diagnosis ER+HER2-MBC: genomic considerations
• Case 2: Can we delay CDK4/6i treatment until the second line?
• Case 3: Selecting therapy after progression of disease on CDK4/6i therapy in patients with PI3K pathway mutations
• Case 4: Selecting treatment for patient with tumor ESR1 mutation
• Case 5: When it's time to move on from endocrine approaches, chemo or ADC?

Educational Session 7: People's Choice – Future Directions in Antibody Drug Conjugates
Location: Hemisfair Ballroom 1-2

Moderator: Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts

• The ABC of ADCs: history, mechanism of action, mechanisms of resistance
  John Lambert, John Lambert Consulting, Cambridge, Massachusetts
• Treating breast cancer with ADCs: clinical role and emerging challenge.
  Giuseppe Curigliano, European Institute of Oncology, Milan, Italy
• The art of developing ADCs: insights at the intersection of academia and industry.
  Ingrid Mayer, AstraZeneca, Frederick, Maryland
• Aiming for the target: Increasing the precision of ADCs through novel biomarkers and innovative molecular constructs.
  Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts

Educational Session 8: Optimizing Local Therapy
Location: Stars at Night 3-4

Moderator: Tari King, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
Patient Advocate: Yvonne Florance, Philadelphia, Pennsylvania

• Surgical Prevention and Management of Lymphedema
  Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida
• Axillary Management: When to Dissect and When to Radiate
  Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada
• Let’s Talk About PBI
  Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York
• Panel Discussion

Poster Session 2
Halls 2-3

(All times are in CST)

Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer: Survival, QOL and biomarkers
Location: Hemisfair Ballroom 1-2

Moderator: Lisa Carey, Lineberger Comprehensive Cancer Center University of North Carolina

Poster Viewing 7:00-7:30
PS2-01: Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial.
Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

PS2-02: Tibremciclib (BPI-16350) plus fulvestrant versus placebo plus fulvestrant for patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: Updated analysis of the phase III study.
Xichun  Hu, Fudan University Cancer Institute, Shanghai, China

PS2-03: Comparative overall survival of CDK4/6is plus an aromatase inhibitor (AI) in HR+/HER2- MBC in the US real-world setting.
Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS2-04: Health related quality of life with first- versus second-line CDK4/6 inhibitor use in advanced breast cancer: results from the phase 3 SONIA trial (BOOG 2017-03).
Noor Wortelboer, Erasmus University Medical Center, Rotterdam, Netherlands

PS2-05: PRESERVE 2: A randomized, phase 3, double-blind trial of trilaciclib or placebo in patients (pts) receiving first-line gemcitabine/carboplatin (GCb) for locally advanced or metastatic triple-negative breast cancer (mTNBC).
Shom Goel, University of Melbourne Peter MacCallum Cancer Centre, Melbourne, Australia

PS2-06: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression.
Yen-Shen Lu, National Taiwan University Hospital, Taipei, Taiwan

PS2-07: Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in Hormone Receptor-Positive/HER2-Negative  Metastatic Breast Cancer (MBC).
Francesco Schettini, Hospital Clinic Barcelona, Barcelona, Spain

PS2-08: Association of MammaPrint® with gene expression pathways predictive of resistance to cyclin-dependent kinase inhibition.
Adam Brufsky, University of Pittsburgh, Pittsburgh, Pennsylvania

PS2-09: Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial.
Guilherme Nader-Marta, Dana-Farber Cancer Institute, New York, New York

PS2-10: Integrating ctDNA and Tumor Fraction Features for Deciphering Molecular Response and Resistance Mechanism to Endocrine Therapy and CDK4/6 Inhibition in Advanced HR-positive Metastatic Breast Cancer.
Hao Liao, Peking University Cancer Hospital, Beijing, China

7:30-7:45 Discussant (PS2-01, PS2-02, PS2-03, PS2-04, PS2-05)
CDK 4/6i
Kari Wiskinski, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS2-06, PS2-07, PS2-08, PS2-09, PS2-10)
Biomarkers
Matthew Goetz, Mayo Clinic, Rochester, Minnesota

8:15-8:30 Panel Q&A

Session 6: Locoregional Therapy
Location: Room 221ABC

Moderator: Mylin Torres, Winshop Cancer Institute of Emory University

PS6-01: The PARP inhibitor rucaparib is a strong radiosensitizer in women with residual triple-negative breast cancer treated concurrently with adjuvant radiotherapy.
Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York

PS6-02: Association of VMAT versus 3D-CRT Radiotherapy Treatment Technique with Acute Toxicity of Regional Nodal Irradiation: A Secondary Analysis of the SAPHIRe Phase III Randomized Clinical Trial.
Chelain Goodman, MD Anderson Cancer Center, Houston, Texas

PS6-03: Post-Mastectomy Proton Therapy Imparts Increased Risk of Capsular Contracture in Reconstructed Breast Cancer Patients.
Mehmet Murat Zerey, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida

PS6-04: Eliminating breast surgery for invasive, hormone-positive breast cancers with an exceptional response to endocrine therapy and ablative radiotherapy: a single-arm, phase 2 trial.
Simona Shaitelman, MD Anderson Cancer Center, Houston, Texas

PS6-05: First report of clinicopathologic characteristics and surgical outcomes of patients in the Avoid axillary Sentinel Lymph node biopsy After Neoadjuvant chemotherapy (ASLAN) trial (KBCSG-28).
Han-Byoel Lee, Seoul National University College of Medicine, Seoul, South Korea

PS6-06: Upstage of N-Stage by Diagnostic Axillary Lymph Node Dissection in Patients w/ Isolated Tumor Cells or Micrometastases in Sentinel/Target Lymph Node after Neoadjuvant Chemotherapy - Results from the Prospective Multicenter AXSANA / EUBREAST 3 Study.
Thorsten Kuehn, University of Ulm, Germany

PS6-07: Clinical and patient reported outcomes in women offered oncoplastic breast conserving surgery as an alternative to mastectomy: 12-month results of the UK ANTHEM multicentre prospective cohort study.
Shelley Potter, University of Bristol Medical School, Bristol, United Kingdom

PS6-08: Quality of life following total mastectomy, breast-conserving surgery, and immediate breast reconstruction in patients with breast cancer: A multicenter cross-sectional study.
Hirohito Seki, Kyorin University School of Medicine, Mikita, Japan

7:30-7:45 Discussant (PS6-01, PS6-02, PS6-03, PS6-04)
Radiation Oncology
Erin Gillespie, University of Washington, Seattle, Washington

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS6-05, PS6-06, PS6-07, PS6-08)
Biomarkers
Alastair Thompson, Baylor College of Medicine, Houston, Texas

8:15-8:30 Panel Q&A

Session 8: Novel HER2 Therapeutics
Location: Stars at Night 1-2

Moderator: Ian Krop, Yale School of Medicine

Poster Viewing 7:00-7:30
PS8-01: ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases..
Ethan (Di) Zhu, ZionPharma, Shanghai, China

PS8-02: A Phase 1 study Evaluating the Safety, Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors.
Xiaoyang Xia, Wuhan Institute of Technology, Wuhan, China

PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03).
William Jacot, Montpellier Cancer Institute and University of Montpellier, Montpellier, France

PS8-04: Targeting clinically advanced breast cancer with conjugated and unconjugated HER2 antibodies: Does copy number matter?
Nicole Odzer, Yale School of Medicine, New Haven, Connecticut

PS8-05: ACE-Breast-08: a phase I study of ARX788, a novel anti-HER2 antibody-drug conjugate, in patients with TKI pretreated HER2 positive advanced breast cancer.
Xiaojia Wang, Zhejiang Cancer Hospital, Hangzhou Institute of  Medica（HIM) , Chinese Academy of Sciences, Zhejiang, China

PS8-06: A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis.
Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

PS8-07: Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer.
Biyun Wang, Fudan University Shanghai Cancer Center, Shanghai, China

PS8-08: Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study.
Herui Yao, Sun Yat-Sen University, Guangzhou, China

PS8-09: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study.
Alberto Montero, University Hospitals Cleveland Medical Center, Cleveland, Ohio

7:30-7:45 Discussant (PS8-01, PS8-02, PS8-03, PS8-04)
Radiation Oncology
Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS8-05, PS8-06, PS8-07, PS8-08, PS8-09)
Biomarkers
Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

8:15-8:30 Panel Q&A

Session 9: ctDNA uses for Minimal Residual Disease testing, tumor evolution, and novel technologies
Location: Stars at Night 3-4

Moderator: Charles Perou, Lineberger Comprehensive Cancer Center University of North Carolina

Poster Viewing 7:00-7:30
PS9-01: Actionable Genomic Alterations in Localized Hormone Receptor Positive (HR+) Breast Cancer and Impact on Clinical Outcomes: Results from Comprehensive Whole Exome Sequencing (WES) and Tumor-Informed circulating tumor DNA (ctDNA) analysis.
Marla Lipsyc-Sharf, UCLA Health, Santa Monica, California

PS9-02: Serial circulating tumor DNA (ctDNA) assessment to predict treatment response and identify genomic evolution in patients with metastatic breast cancer (mBC).
Laura Linville, Johns Hopkins Kimmel Cancer Center, Washington, D.C.

PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study.
Eleanor Taranto, University of Pennsylvania, Philadelphia, Pennsylvania

PS9-04: Evaluating racial genomic differences in de novo metastatic breast cancer utilizing ctDNA: results from a large multi-center consortium.
Emily Podany, Washington University School of Medicine, St. Louis, Missouri

PS9-05: Somatic Structural Variation in Breast Cancer and its Application in Longitudinal Analysis of Circulating Tumor DNA in Early Breast Cancer.
Mitchell Elliott, University of Toronto, Toronto, Canada

PS9-06: Tracking structural variants in ctDNA using a high-sensitivity assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.
Hervé Bonnefoi, Bordeaux Institute of Oncology, Bordeaux, France

PS9-07: Epigenomic Characterization of ER Transcriptional Activation via Liquid Biopsy.
Jonathan Beagan, Precede Biosciences, Boston, Massachusetts

PS9-08: Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC).
Albert Grinshpun, Dana-Farber Cancer Institute, Boston, Massachusetts

7:30-7:45 Discussant  (PS9-01, PS9-03, PS9-04, PS9-06)
Evaluating Minimal Residual Disease
Yara Abdou, University of North Carolina School of Medicine, Chapel Hill, North Carolina

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS9-02, 9-05, PS6-07, PS9-08)
ctDNA in tumor evolution
Marija Balic, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania

8:15-8:30 Panel Q&A

Session 15: Survivorship – Biomarker predictors and other survival-associated factors
Location: Hemisfair Ballroom 3

Moderator: Lindsay Peterson, Washington University Siteman Cancer Center, St. Louis, Missouri

Poster Viewing 7:00-7:30
PS15-01: Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.
Margaux Wooster, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York

PS15-02: Genome-wide association study (GWAS) of aromatase inhibitor musculoskeletal toxicity (AIMT) among early-stage breast cancer (BC) survivors.
Pietro Lapidari, Institut de Cancérologie Gustave Roussy, Villejuif, France

PS15-03: Retrospective study of GLP-1 Receptor Agonists in Breast Cancer Survivors: Weight Loss and Patient Outcomes
Jasmine Sukumar, MD Anderson Cancer Center, Houston, Texas

PS15-04: Impact of a dietitian and nurse-led survivorship clinic utilizing ePRO collection on body composition and muscle strength in early-stage breast cancer: Results from the Linking You to Support and Advice (LYSA) Randomized Control Trial.
Katie E. Johnston, University College Cork, Cork, Ireland

PS15-05: Breast Cancer Patients with High-Risk Disease Characteristics have Proportionately Higher Risk of Mortality from Non-Breast Cancer Related Causes in both Non-Metastatic and Metastatic Disease.
Shipra Gandhi, Roswell Park Comprehensive Cancer Center, Buffalo, New York

PS15-06: Ability to comply with placebo predicts overall survival in randomized trial.
Tara Sanft, Yale School of Medicine, New Haven, Connecticut

PS15-07: Late effects of chemotherapy on patient-reported falls among older breast cancer survivors.
Inimfon Jackson, MD Anderson Cancer Center, Houston, Texas

PS15-08: Factors and trends associated with alcohol intake in late survivorship for patients with breast cancer.
Sanjna Rajput, Mayo Clinic, Rochester, Minnesota

7:30-7:45 Discussant (PS15-01, PS15-02, PS15-03, PS15-04)
Weight and Biomarkers
Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS15-05, PS15-06, PS15-07, PS15-08)
Predictors of Survival
Maryam Lustberg, Yale University, New Haven, Connecticut

8:15-8:30 Panel Q&A

Plenary Lecture
Location: Hall 1

Moderator: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas

The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes
Melissa B. Davis, Morehouse School of Medicine, Atlanta, Georgia

Location: Hall 1

Moderator: Michael Gnant, Medical University of Vienna, Vienna, Austria, and Zhi-Ming Shao, Fudan University Shanghai Cancer Center, Shanghai, China

GS2-01: Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.
Icro Meattini, University of Florence, Florence, Italy

GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina

GS2-03: Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators.
Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland

GS2-04: Discussant about GS2-01, 02, and 03
Elinor Sawyer, King’s College London, London, United Kingdom

GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina

GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts

GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany

GS2-08: Discussant Puneet Singh, MD Anderson Cancer Center, Houston, Texas

GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
Hongchao Pan, University of Oxford, Oxford, United Kingdom

GS2-10: A long-term image-derived AI risk model for primary prevention of breast cancer.
Mikael Eriksson, Karolinska Institutet, Solna, Sweden

GS2-11: APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.
Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York

GS2-12: AFT-38 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast Cancer
Otto Metzger, Dana Farber Cancer Institute, Boston, Massachusetts
View the Abstract

GS2-13: Discussant Sara Hurvitz, "Beyond proof of concept: evidence to support use of CDK4/6i for HER, too"

Location: Hall 1

Moderator: Carlos Arteaga, UT Southwestern, Dallas, Texas

RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.
Judy Boughey, Mayo Clinic, Rochester, Minnesota

RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.
Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH

RF2-03: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).
Steffi Hartmann, University of Rostock, Rostock, Germany

RF2-04: Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO).
Melanie Machiels, Universiteit Antwerpen, Antwerp, Belgium

RF2-05: Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study.
Demet Özcan, Aarhus University Hospital, Aarhus, Denmark

RF2-06: A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.
Luke Peppone, University of Rochester Medical Center, Rochester, New York

Poster Session 3
Halls 2-3

Risk Reduction and Early Detection: The Future of Cancer Genetics Is Here
Location: Stars at Night 3-4

Moderator: Claudine Isaacs, Georgetown University, Washington, DC
Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia

• Saturation Genome Editing-Based Functional and Clinical Classification of VUS in BRCA2
  Fergus Couch, Mayo Clinic, Rochester, Minnesota
• Updates on Risk Prediction Models
  Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom
• Reversion Mutations in BRCA1/2 in Response to Therapy 
  Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
• Panel Discussion

Patient Advocates group photo
Location: Advocacy Lounge, Room 220

Molecular Tumor Board
Location: Stars at Night 1-2

Moderator: Phillipe Afthimos, Insitut Jules Bordet, Brussels, Belgium

• Dara Aisner, University of Colorado Medical School, Aurora, Colorado
• Jorge Reis-Filho, AstraZeneca, Gaithersburg, Maryland
• Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada
• Jenna Canzoniero, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland
• Bob Riter, Cornell University, Ithaca, New York

Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies
Location: Stars at Night 1-2

Moderator: Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York

• Omission of Axillary Staging in ER+ Disease What is The Data?
  Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts
• Omission of Axillary Staging in ER+ Disease Implications for Radiotherapy
  Jean Wright, UNC School of Medicine, Chapel Hill, North Carolina
• Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy
  Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia
• Radiation Post pCR
  Richard Zellars, Indiana University School of Medicine, Indianapolis, Indiana
• Panel Discussion

State of the Art: Revolutionizing Diagnosis and Discovery with Artificial Intelligence
Location: Stars at Night 3-4 

Moderator: Fred Howard, University of Chicago, Chicago, Illinois

• Pathology
  Kun-Hsing Yu, Harvard University, Cambridge, Massachusetts
• Imaging and Screening
  Ritse Mann, Netherlands Cancer Institute, Amsterdam, Netherlands
• Drug Discovery, Deep Learning, and Large Data Management 
  Erika Hamilton, Sarah Cannon Research Institute, Nashville, Tennessee
• Panel Discussion

AACR Distinguished Lecture in Breast Cancer Research
Location: Stars at Night 1-2
Moderator: Luisa Arispe, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Steffi Oesterreich, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania

Educational Session 9: Artificial Intelligence in the Clinic
Location: Stars at Night 3-4

Moderator: Debra Patt, Texas Oncology-Austin Central, Austin, Texas
Patient Advocate: Terri Crudup, Phoenixville, Pennsylvania

• Hazards and Opportunities
  Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts
• Beyond Chat GPT: Generative AI in Healthcare 
  Ian Maurer, Genomoncology, Cleveland, Ohio
• Digital Tools for Clinical Practice
  Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
• Panel Discussion

Educational Session 10: Immunotherapy
Location: Stars at Night 1-2

Moderator: Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

• Immunotherapy in Early ER Positive Breast Cancer 
  Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland
• Optimization of Treatment in TNBC
  Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
• The Future of Immunotherapy 
  Evanthia Roussos Torres, University of Southern California, Los Angeles, California
• Panel Discussion

Educational Session 11: Mind the Gap—Breast Cancer in Older Adults
Location: Hemisfair Ballroom 3

Moderator: Mina Sedrak, UCLA David Geffen School of Medicine, Los Angeles, California
Patient Advocate: Sandi Stanford, San Antonio, Texas

• Biology - the Aging Immune System with Hormonal Changes 
  Lajos Pusztai, Yale School of Medicine, New Haven, Connecticut
• Defining and Avoiding Low Value Surgical Therapy 
  Christina Minami, Brigham and Women's Hospital, New York City
• Systemic Therapies
  Hans Wildiers, University Hospital Leuven, Leuven, Belgium
• Panel Discussion

Educational Session 12:
The Biology and Treatment Implications of Organ Specific Metastases
Location: Hemisfair Ballroom 1-2

Moderator: Heide Ford, University of Colorado Denver School of Medicine, Denver, Colorado
Patient Advocate: Christine Hodgdon, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

• Brain metastasis focusing on how astrocytes in the brain ME affect metastasis.
  Diana Cittelly, University of Colorado Anschutz Medical Campus, Aurora, Colorado
• Liver Metastases 
  Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium
• Bone Metastases
  Rachelle Johnson, Vanderbilt University Medical Center, Nashville Tennessee
• Panel Discussion

Concurrent Poster Spotlight Sessions 16-19

Session 16: Polygenic Risk
Location: Hemisfair Ballroom 3

Moderator: Banu Arun, MD Anderson Cancer Center, Houston, Texas
 

Poster Viewing 5:30-6:00
PS16-01: Longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors.
Timothy Simmons, Freeman Hospital Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

PS16-02: Polygenic risk score as an aid for risk stratification in benign breast disease.
Kush Lohani, Mayo Clinic, Rochester, Minnesota

PS16-03: Isoform-level analyses of breast cancer and its subtypes uncover extensive genetic risk mechanisms undetected at the gene-level.
Taylor Head, Bhattacharya Lab for Computational Genomics, Houston, Texas

PS16-04: Differences in breast cancer phenotype by germline TP53 variant functional classification.
Renata Sandoval, Dana-Farber Cancer Institute, New York, New York

PS16-05: Primary breast cancer prevention using oral endoxifen.
Per Hall, Karolinska Institutet, Stockholm, Sweden

PS16-07: Quantitative breast density measures and radiomic parenchymal phenotypes improve breast cancer risk prediction among Black and White women undergoing mammography screening.
Anne Marie McCarthy, University of Pennsylvania, Philadelphia, Pennsylvania

PS16-08: Trends in LCIS Incidence from 2000-2020 Mirror USPSTF Screening Guidelines: A SEER Registry Analysis.
Anna C. Beck, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

PS16-09: A decision support intervention to promote the use of preventive therapy among women at high risk for invasive breast cancer.
Inimfon Jackson, MD Anderson Cancer Center, Houston, Texas

6:00-6:15 Discussant (PS16-01, PS16-02, PS16-03, PS16-04, PS16-05)
Genetic and Polygenetic Risk for Breast Cancer
Fergus Couch, Mayo Clinic, Rochester, Minnesota

6:15-6:30 Panel Q&A

6:30-6:45 Discussant (PS16-07, PS16-08, PS16-09)
Contemporary approaches to high-risk screening and prevention
Sonya Reid, Vanderbilt University Medical Center, Nashville, Tennessee

6:45-7:00 Panel Q&A

Session 17: Early Triple Negative Breast Cancer
Location: Stars at Night 1-2

Moderator: Hope Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center
 

Poster Viewing 5:30-6:00

PS17-01: Spatial transcriptomics identifies molecular patterns predictive of response to neoadjuvant chemotherapy in triple-negative breast cancer.
Isobelle Wall, King’s College, London, United Kingdom

PS17-02: Molecular and Immune Landscape of Metaplastic Triple Negative Breast Cancer Compared with Invasive Ductal Triple Negative Breast Cancer.
Pooja Advani, Mayo Clinic, Jacksonville, Florida

PS17-03: Real World Adjuvant Capecitabine Utilization and Patient Outcomes Among Patients With Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.
Ava Strahan, Ohio State University Stover Lab for Clinical Computational Oncology, Columbus, Ohio

PS17-04: Implications of Adjuvant Chemotherapy in Small Triple-Negative Breast Cancer.
Hannah Hackbart, Cedar-Sinai Hospital, Beverly Hills, California.

PS17-05: Use and benefit of neoadjuvant versus adjuvant chemotherapy in node-negative, T1 triple negative breast cancer.
Jesus Anampa, Albert Einstein College of Medicine, New York, New York

PS17-06: Neutrophil-to-lymphocyte ratio (NLR) predicts long-term survival in early triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT).
Gabriel Polho, Instituto do Câncer do Estado de São Paulo – ICESP, São Paulo, Brazil

PS17-07: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in high-risk triple-negative breast cancer (TNBC) – a subgroup analysis of the neoadjuvant neoMono trial.
Hans-Christian Kolberg, Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany

PS17-08: Association of antibiotic exposure with pathologic complete response in patients with non-metastatic triple-negative breast cancer receiving neoadjuvant chemotherapy and pembrolizumab.
Alexis Espinal, University of Michigan Medical School, Ann Arbor, Michigan

PS17-09: Immune landscape and clinical features of acquired resistance to immune checkpoint blockade in triple negative breast cancer.
Veerle Geurts, Netherlands Cancer Institute, Amsterdam, Netherlands

PS17-10: Genomic and transcriptomic analyses of residual invasive triple-neg breast cancer after neoadjuvant chemotherapy in prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab + capecitabine versus capecitabine; KCSG-BR18-21).
Seock-Ah Im, Seoul National University Hospital, Seoul, South Korea

6:00-6:15 Discussant (PS17-01, PS17-02, PS17-03, PS17-04, PS17-05)
Topic 1
Filipa Lynce, Dana-Farber Cancer Institute, Boston, Massachusetts

6:15-6:30 Panel Q&A

6:30-6:45 Discussant (PS17-06, PS17-07, PS17-08, PS17-09, PS17-10)
Topic 2
Rita Nanda, University of Chicago, Chicago, Illinois

6:45-7:00 Panel Q&A

Session 18: Advancing our understanding of invasive lobular carcinoma: Potential to develop personalized therapeutic strategies?
Location: Stars at Night 3-4

Moderator: Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

Poster Viewing 5:30-6:00
PS18-01: Spatial Transcriptomics-Derived Classification of Invasive Lobular Carcinoma: Associations with Clinical, Genomic Characteristics, and Prognosis.
Matteo Serra, Institut Jules Bordet, Brussels, Belgium

PS18-02: E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma.
Lounes Djerroudi, Institut Curie, Paris, France

PS18-03: GeoMx DSP and CosMx single cell spatial transcriptomics for molecular characterization of invasive lobular breast cancer cells and their microenvironment.
Lynda Bennett, UT Southwestern Medical Center, Dallas, Texas

PS18-04: Tumor intrinsic and extrinsic characteristics of invasive lobular carcinomas.
Lise Mangiante, Stanford Cancer Center, Palo Alto, California

PS18-05: Clinical Management and Oncological Outcomes of Pure Pleomorphic and Florid Lobular Carcinoma in Situ of the Breast: Results from the MultiLCIS Study.
Massimo Ferrucci, Veneto Institute of Oncology, Padua, Italy.

PS18-06: Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma.
Rinath Jeselsohn, Dana-Farber Cancer Institute, Boston, Massachusetts

PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamide.
Jennifer Richer, University of Colorado School of Medicine, Aurora, Colorado

PS18-08: MDA iLobulaRx: An Advanced Clinico-Patho-Therapeutic Tool for Risk Stratification in Early-Stage Invasive Lobular Carcinoma.
Jason Mouabbi, MD Anderson Cancer Center, Houston, Texas

PS18-09: Endocrine Response in Women with Invasive Lobular Carcinoma (TBCRC 037): A Multicenter Randomized Clinical Tria9.
Priscilla McAuliffe, University of Pittsburgh, Pittsburgh, Pennsylvania

6:00-6:15 Discussant (PS18-01, PS18-02, PS18-03, PS18-04)
Translational topics in Lobular Breast Cancer
Christos Sotirou, Institut Jules Bordet, Brussels, Belgium

6:15-6:30 Panel Q&A

6:30-6:45 Discussant (PS18-05, PS18-06, PS18-07, PS18-08, PS18-09)
Advancing Clinical Outcomes
Rita Mukhtar, University of California San Francisco, San Francisco, California

6:45-7:00 Panel Q&A

Session 19: “A penny for your thoughts.” How cost influences care.
Location: Hemisfair Ballroom 1-2

Moderator: Debra Patt, Texas Oncology, Austin, Texas

Poster Viewing 5:30-6:00

PS19-01: Medication Nonadherence and Financial Toxicity Among Patients with Metastatic Breast Cancer on Cyclin Dependent Kinase 4/6 Inhibitors.
Claire Sathe, Columbia University Herbert Irving Comprehensive Cancer Center

PS19-02: Economic Impact of Concurrent Tissue and Circulating Tumor DNA Molecular Profiling In Advanced Breast Cancer Patients
Zach Rivers, Tempus AI, Burlington, Vermont

PS19-03: Contemporary patterns of Medicare Utilization and Spending on Herceptin and its Biosimilars in Breast Cancer.
Charmi Bhanushali, Saint Vincent Hospital, Worcester, Massachusetts

PS19-04: Exploring the broad societal value of pembrolizumab in triple-negative breast cancer in Canada.
Kate Young, Royal Marsden Hospital, London, United Kingdom

6:00-6:15 Discussant
Financial Toxicity
Stephen Schleicher, Tennessee Oncology, Nashville, Tennessee

6:15-6:30 Panel Q&A

SABCS Celebration

Texas Ballroom, Grand Hyatt San Antonio Hotel

(All times are in CST)

Concurrent Poster Spotlight Sessions 10-14

Session 10: Addressing Racial Disparities in Breast Cancer Outcomes
Location: Hemisfair Ballroom 3

Moderator: Yara Abdou, University of North Carolina School of Medicine

Poster Viewing 7:00-7:30
PS10-01: Racial differences in the prevalence of biomarker alterations, treatment patterns, and clinical outcomes in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: A national cohort study.
Pegah Farrokhi, University of Minnesota, Minneapolis, Minnesota

PS10-02: Pre-diagnosis Physical Activity and Racial Disparities in Breast Cancer Survival Outcomes: a Multiethnic Cohort Study.
Yijia Sun, University of Chicago, Chicago, Illinois

PS10-03: Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: A SEER-Medicare Database Analysis.
Karissa Britten, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California

PS10-04: Identifying Risk Factors for High Allostatic Load in a Racially/Ethnically Diverse Cohort of Breast Cancer Patients.
Anna Vaynrub, Columbia University Vagelos College of Physicians and Surgeons, New York, New York

PS10-05: Door-to-door Breast Cancer Screening in 22,278 populaces from Feb. 2020-April 2024: Breast Cancer Hub's Trendsetting Grassroots Sustainable Solutions, overcoming the Disparity, & Challenges in the Rural Remote Villages in Poverty, of Assam, India.
Lopamudra Das Roy, Breast Cancer Hub, Concord, North Carolina

PS10-06: Access to Innovative Medicines for Advanced Breast Cancer as a Catalyst for Health Systems Strengthening in Low- and Middle-Income Countries.
Fatima Cardoso, Champalimaud Clinical Center, Lisbon, Portugal

PS10-07: The Molecular Subtypes of Breast Cancer: A Single Institution Experience after a Decade of the Syrian War.
Ayla Kouli, Damascus University, Damascus, Syria

PS10-08: Appalachian Mobile Mammogram Program Achieves Unprecedented Outcomes by Repeatedly Reaching Underserved Women.
John L. Bell, University of Tennessee Medical Center, Knoxville, Tennessee

PS10-09: Occupational Pesticide Exposure and Poor Prognosis Breast Cancer in Brazilian Women: Epidemiological Insights and Molecular Mechanisms.
Carolina Panis, Universidade Estadual do Oeste do Paraná, Francisco Beltrão, Brazil

7:30-7:45 Discussant (PS10-01, PS10-02, PS10-03, PS10-04)
Bridging the Gap: Addressing Racial Disparities in Breast Cancer Outcomes
Dame’ Idossa, University of Minnesota Medical School, Minneapolis, Minnesota

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS10-05, PS10-06, PS10-07, PS10-08, PS10-09)
Advancing Global Health Equity: Addressing Disparities in Low-Resource Settings
Stephen Kimani, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

8:15-8:30 Panel Q&A

Session 11: Imaging to Guide Breast Cancer Treatment – Molecular Imaging and AI
Location: Hemisfair Ballroom 1-2

Moderator: David Mankoff, Perelman School of Medicine University of Pennsylvania

Poster Viewing 7:00-7:30
PS11-01: [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142.
Hannah Linden, Fred Hutchinson Cancer Center, Seattle, Washington

PS11-02: [18F]fluoroestradiol (FES) PET/CT to guide 2nd line treatment decision in patients with ER-positive HER2-negative advanced breast cancer (ABC) progressing on 1st line aromatase inhibitor and CDK4/6 inhibitor: early results of the ESTROTIMP trial.
Francois-Clement Bidard, Institut Curie, Paris, France

PS11-03: Comparative analysis of [18F]FES- and [18F]FDG-PET in patients with metastatic ER+  lobular breast cancer.
Jasmine Moustaquim, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands

PS11-05: Novel 4D radiomics applied to dynamic FES PET images to improve prediction of ER-positive breast cancer outcomes for ER-targeted therapy.
Carla Zeballos Torrez, Penn Medicine University of Pennsylvania. Philadelphia, Pennsylvania

PS11-06: Leveraging AI to Predict Recurrence-Free Survival in Breast Cancer Patients through Image-Based assessment of Tumor Characteristics.
Poornima Saha, NorthShore University HealthSystem, Glenview, Illinois

PS11-07: Predicting the response of locally advanced breast cancer to neoadjuvant therapy using MRI-based mathematical modeling of the I-SPY 2 dataset.
Reshmi Patel, University of Texas at Austin Center for Computational Oncology, Austin, Texas

PS11-08: MRI improves multi-modal AI system for breast cancer diagnosis and prognosis.
Yanqi Xu, New York University, New York, New York

PS11-09: Improving risk estimation for women with dense breasts.
Shu (Joy) Jiang, Washington University School of Medicine, St. Louis, Missouri

7:30-7:45 Discussant (PS11-01, PS11-02, PS11-03, PS11-05)
Molecular Imaging to Assess ER+ Breast Cancer
Laura Kenney, Imperial College London, London, United Kingdom

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS11-06, PS11-07, PS11-08, PS11-09)
AI and Imaging to Guide Breast Treatment
Aimilia Gastounioti, Washington University School of Medicine, St. Louis, Missouri

8:15-8:30 Panel Q&A

Session 12: Immunobiology Impact on Therapeutic Efficacy
Location: Room 221ABC

Moderator: Lajos Pusztai, Yale School of Medicine, New Haven, Connecticut
 

Poster Viewing 7:00-7:30
PS12-01: Olaparib-induced early dynamics of tumor immune microenvironment in triple-negative or ER-low breast cancer: insights from a window of opportunity MEDIOLA trial of olaparib and durvalumab with serial biopsies.
Jiwon Koh, Seoul National University College of Medicine, Seoul, South Korea

PS12-02: CXCL11 in the tumor immune microenvironment modulates resistance to endocrine therapy in hormone receptor-positive breast cancer.
Fabiana Napolitano, UT Southwestern Medical Center, Dallas, Texas

PS12-03: Molecular characterization of the NeoPalAna Endocrine Resistant (ET-R) Cohort: implications for CDK4/6 inhibitor (CDK4/6i) and ET resistance mechanisms in primary estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC).
Tim Kong, Washington University School of Medicine, St. Louis, Missouri

PS12-04: HDACi combined with anthracycline elicits interactions between MHC-II+ triple-negative breast cancer and CD69+CD4+Trm orchestrating synergistic immunotherapy.
Zehao Wang, Fudan University Shanghai Cancer Center, Shanghai, China

PS12-05: PARP7 inhibition combined with radiotherapy overcomes ICI resistance in breast cancer.
Lynn Lerner, University of North Carolina School of Medicine, Chapel Hill, North Carolina

PS12-06: An In Situ Tumor Vaccine Against Triple Negative Breast Cancer.
Nicole McCuen, UT Southwestern Medical Center, Dallas, Texas

PS12-07: DNA methyltransferase 3A (DNMT3A) protein expression in triple-negative breast cancer (TNBC): Impact on clinical outcomes, gene expression, and tumor microenvironment.
Roberto Leon-Ferre, Mayo Clinic, Rochester, Minnesota

PS12-08: Biological sex-linked immune modulation but not cross-sex estrogen therapy reduces the efficacy of PARP inhibition in the treatment of Brca1 breast tumors.
Jan Heng, Beth Israel Deaconess Medical Center, Boston, Massachusetts

PS12-09: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk, early-stage triple-negative breast cancer: Overall survival and subgroup results from the phase 3 KEYNOTE-522 study.
Rebecca Dent, National Cancer Center Singapore, Singapore

7:30-7:45 Discussant (PS12-01, PS12-02, PS12-03, PS12-04)
Immunobiology 1
Giampaolo Bianchini, Vita-Salute San Raffaele University, Milan, Italy

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS12-05, PS12-06, PS12-07, PS12-08, PS12-09)
Immunobiology 2
Antonio Giordano, Harvard University, Cambridge, Massachusetts

8:15-8:30 Panel Q&A

Session 13: Molecular determinants of therapeutic response and resistance - Spotight on CDK 4/6i and ADCs
Location: Stars at Night 1-2

Moderator: Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

Poster Viewing 7:00-7:30
PS13-01: Evaluation of breast cancer stem cell gene expression signatures in single-cell RNA sequencing (scRNAseq) data from the OPPORTUNE and FELINE trials, and the association with treatment resistance laparib-induced early dynamics of tumor immune microenvironment.
Peter Hall, Barts Cancer Institute Queen Mary University of London, London, United Kingdom

PS13-03: Decoupling of oestrogen response and proliferation in post-menopausal ER+ HER2- primary breast cancer after 2-week aromatase inhibitor treatment in the POETIC trial.
Istvan Kleijn, The Institute of Cancer Research: Royal Cancer Hospital, London, United Kingdom

PS13-04: DREAM complex assembly and stable cell cycle control underlies long-term clinical response to CDK4/6 inhibition.
Rei Kudo, Memorial Sloan Kettering Cancer Center, New York, New York

PS13-05: The UNDERSTAND trial: a multi-omic platform for investigating CDK4/6 inhibitors resistance mechanisms in HR+ advanced breast cancer.
Andrea Vingiani, University of Milan, Milan, Italy

PS13-07: Enhancing T-DXd Efficacy in HER2-positive Breast Cancer Resistant to HER2 ADC by Non-biased Kinase-related Target Screening.
Jangsoon Lee, University of Hawai’i Cancer Center, Honolulu, Hawaii

PS13-08: ARID1A as a Novel Regulator of Trop2-ADC Efficacy in Trop2-Low Hormone Receptor–Positive Breast Cancer.
Nanae Ogata, University of Hawai’i at Manoa, Honolulu, Hawaii

PS13-09: Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multi-omic Molecular Profiling.
George W. Sledge Jr., Stanford Women’s Cancer Center, Palo Alto, California

7:30-7:45 Discussant (PS13-01, PS13-03, PS13-04, PS13-05)
Endocrine Therapy
Amy Jo Chien, University of California San Francisco, San Francisco, California

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS13-07, PS13-08, PS13-09)
Chemotherapy 
Barbara Pistilli, Gustave Roussy Cancer Center, Villejuif, France

8:15-8:30 Panel Q&A

Session 14: Brain Metastasis
Location: Stars at Night 3-4

Moderator: William Gradishar, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Poster Viewing 7:00 – 7:30
PS14-01: Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Update on Phase 1 dose escalation study.
Andrew Brenner, UT Health Mays Cancer Center, San Antonio, Texas

PS14-02: A Prospective Phase II Trial of Hypofractionated Stereotactic Radiotherapy (FSRT) for Patients with 1-10 Brain Metastases from Breast Cancer.
Jin Meng, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

PS14-03: Updated analyses from a Phase I study of the brain-penetrant oral SERD- SIM0270 in patients with ER-positive,HER2-negative advanced breast cancer.
Qingyuan Zhang, Harbin Medical University Cancer Hospital, Harbin, China

PS14-04: SIM0270, a brain-penetrant oral SERD, in combination with everolimus in patients with ER+/HER2- advanced breast cancer: the phase Ib study.
Jian Zhang, Fundan University Shanghai Cancer Center, Shanghai, China

PS14-05: Clinically actionable genomic alterations in breast cancer brain metastases.
Gaia Griguolo, Veneto Institute of Oncology, Padua, Italy

PS14-06: Gene expression profiling of brain metastases and matched primary breast tumours with focus on the immune system and tumour microenvironment.
Anna Thulin, University of Gothenburg, Gothenburg, Sweden

PS14-07: Spatial transcriptomics of matched breast cancer brain metastases and primary tumors identifies a brain-specific immune-suppressive transcriptional program.
Patrick Kurnia, Dana-Farber Cancer Institute, Boston, Massachusetts

PS14-08: Targeting CXCL1-CXCR2 axis blocks brain metastasis in inflammatory breast cancer.
Xiaoding Hu, MD Anderson Cancer Center, Houston, Texas

PS14-09: Central Nervous System as the Primary Site of First Relapse in Patients with Triple-Negative Breast Cancer Achieving Pathological Complete Response After Neoadjuvant Treatment.
Davide Massa, Instituto Ongcologio Veneto IOV – IRCCS, Padua, Italy

PS14-10: Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL) & neurological function in patients (pts) w/ HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINY-Breast12(DB-12) results
Nadia Harbeck, Ludwig-Maximilians-Universitӓt München (LMU), Munich, Germany

7:30-7:45 Discussant (PS14-01, PS14-02, PS14-03, PS14-04, PS14-05)
Topics in Clinical Care
Carey Anders, Duke University Cancer Center, Durham, North Carolina

7:45-8:00 Panel Q&A

8:00-8:15 Discussant (PS14-06, PS14-07, PS14-08, PS14-09, PS14-10)
Topics in Translational Therapeutics
Andrew Brenner, UT Health Mays Cancer Center, San Antonio, Texas

8:15-8:30 Panel Q&A

Plenary Lecture
Location: Hall 1

Moderator: Virginia Kaklamani, UT Health Mays Cancer Center, San Antonio, Texas

Cell Atlases as Roadmaps in Cancer Immunology
Walid Khaled, University of Cambridge, Cambridge, United Kingdom

General Session 3
Location: Hall 1

Moderators: Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan, and Reshma Jagsi, Emory University, Atlanta, Georgia

GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy.
Nicholas Turner, Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom

GS3-02: Discussant about GS3-01
Ian Krop, Yale School of Medicine, New Haven, Connecticut

GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer.
Nan Chen, University of Chicago Medicine, Chicago, Illinois

GS3-04: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.
Sherko Kuemmel, German Medical Institute, Berlin, Germany

GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.
Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania

GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial.
Zhi-Ming Shao, Fudan University, Shanghai, China

GS3-07: Discussant about GS3-05 and 06
Giampaolo Bianchini, Vita-Salute San Raffaele University, Milano, Italy

GS3-08: In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss.
Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer.
Brooke Felsheim, UNC School of Medicine, Chapel Hill, North Carolina

GS3-11: Discussant about GS3-09 and 3-10
Fred Howard, University of Chicago Medicine, Chicago, Illinois

Rapid Fire 3
Location: Hall 1

Moderator: Peter Fasching, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Germany

RF3-01: TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort.
Erica Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

RF3-02: Efficacy of adjuvant avelumab by PD-L1, tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer: secondary and exploratory endpoints of the phase III A-BRAVE trial.
Maria Vittoria Dieci, University of Padua, Padua, Italy

RF3-03: Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial.
Olivier Trédan, Centre Lèon Bèrard, Lyon, France

RF3-04: NRG-BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer.
Vicente Valero, MD Anderson Cancer Center, Houston, Texas

RF3-05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP).
Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

RF3-06: Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy: Results from Alliance A221803: A Multicenter Phase III Randomized Clinical Trial
Kimberly Corbin, Mayo Clinic, Rochester, Minnesota

RF3-07: ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy.
Daniel Rea, University of Birmingham, Birmingham, United Kingdom

Poster Session 5
Halls 2-3

The Pathologists Conundrum: IHC Testing in Breast Cancer
Location: Room 221ABC

Moderator: David Rimm, Yale School of Medicine, New Haven, Connecticut

• A Brief History of IHC in Breast Cancer and ASCO CAP Guidelines
  Kim Allison, Stanford University/Stanford Cancer Institute, Palo Alto, California
• FDA Perspectives on IHC testing in breast cancer drug development
  Reena Philip, FDA, Gaithersburg, Maryland
• Evaluation of the accuracy of Reading IHC
  Giuseppe Viale, European Institute of Oncology, Milan, Italy
• Evaluation of the Accuracy of Digital Measuring
  Andrew Beck, Path AI, Boston, Massachusetts

Risk Reduction and Early Detection: New Directions in Breast Cancer Prevention
Location: Stars at Night 3-4

Moderator: Gretchen Gierach, National Cancer Institute, Bethesda, Maryland

• Prevention Vaccines: Where Are We Now and Where Are We Going?
  Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania
• Can We Use Biomarkers to Implement Prevention?
  Seema Khan, Northwestern University Feinberg School of Medicine, Chicago, Illinois
• From Bench to Clinical Trial: A New Target for Breast Cancer Prevention 
  Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
• Panel Discussion

Debate: All Patients Should be Offered Universal Germline Genetic Testing
Location: Stars at Night 3-4

Moderator: Andrew Tutt, The Institute of Cancer Research, London, United Kingdom

• Opening Remarks and Polling
• Debate For
  Allison Kurian, Stanford University, Palo Alto, California
• Debate Against
  Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada
• Closing Remarks and Polling

Year in Review
Location: Stars at Night 1-2

Moderators: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas; and Virginia Kaklamani, UT Health Mays Cancer Center, San Antonio, Texas

• Basic Science
  Neil Vasan, Columbia University, New York, New York
• Translational Science Updates 
  Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York
• Early Breast Cancer Updates
  Janice Tsang, University of Hong Kong, Hong Kong, China
• Advanced Breast Cancer Updates 
  Michael Danso, Virginia Oncology Associates, Norfolk, Virginia

View from the Trenches
Location: Stars at Night 1-2

Moderator: Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas
Patient Advocate: Stacey Tinianov, Santa Cruz, California

• Medical Oncology
  Cristina Saura, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
  Antonio Wolff, Johns Hopkins Medicine, Baltimore, Maryland

• Radiation Oncology
  Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York

• Surgical Oncology
  Alastair Thompson, Baylor College of Medicine, Houston, Texas